O	0	7	Changes
O	8	10	in
O	11	15	bone
O	16	23	mineral
O	24	31	density
O	32	34	at
O	35	36	3
O	37	42	years
O	43	45	in
O	46	60	postmenopausal
O	61	66	women
O	67	76	receiving
B-intervention	77	88	anastrozole
I-intervention	89	92	and
I-intervention	93	104	risedronate
O	105	107	in
O	108	111	the
O	112	116	IBIS
O	116	117	-
O	117	119	II
O	120	124	bone
O	125	133	substudy
O	133	134	:
O	135	137	an
O	138	151	international
O	151	152	,
O	153	159	double
O	159	160	-
O	160	165	blind
O	165	166	,
O	167	177	randomised
O	177	178	,
O	179	186	placebo
O	186	187	-
O	187	197	controlled
O	198	203	trial
O	203	204	.

O	205	214	Aromatase
O	215	225	inhibitors
O	226	233	prevent
O	234	240	breast
O	241	247	cancer
O	248	250	in
O	251	265	postmenopausal
O	266	271	women
O	272	274	at
O	275	279	high
O	280	284	risk
O	285	287	of
O	288	291	the
O	292	299	disease
O	300	303	but
O	304	307	are
O	308	318	associated
O	319	323	with
O	324	335	accelerated
O	336	340	bone
O	341	345	loss
O	345	346	.

O	347	349	We
O	350	358	assessed
O	359	372	effectiveness
O	373	375	of
O	376	380	oral
O	381	392	risedronate
O	393	396	for
O	397	407	prevention
O	408	410	of
O	411	420	reduction
O	421	423	in
O	424	428	bone
O	429	436	mineral
O	437	444	density
O	445	446	(
O	446	449	BMD
O	449	450	)
O	451	456	after
O	457	458	3
O	459	464	years
O	465	467	of
O	468	474	follow
O	474	475	-
O	475	477	up
O	478	480	in
O	481	482	a
O	483	489	subset
O	490	492	of
O	493	501	patients
O	502	504	in
O	505	508	the
O	509	513	IBIS
O	513	514	-
O	514	516	II
O	517	522	trial
O	522	523	.

O	524	527	The
O	528	534	double
O	534	535	-
O	535	540	blind
O	541	545	IBIS
O	545	546	-
O	546	548	II
O	549	554	trial
O	555	564	recruited
B-total-participants	565	569	3864
B-eligibility	570	577	healthy
I-eligibility	577	578	,
I-eligibility	579	593	postmenopausal
I-eligibility	594	599	women
I-eligibility	600	602	at
I-eligibility	603	612	increased
I-eligibility	613	617	risk
I-eligibility	618	620	of
I-eligibility	621	627	breast
I-eligibility	628	634	cancer
O	635	638	and
O	639	647	randomly
O	648	657	allocated
O	658	662	them
O	663	667	oral
O	668	679	anastrozole
O	680	681	(
O	681	682	1
O	683	685	mg
O	685	686	/
O	686	689	day
O	689	690	)
O	691	693	or
O	694	701	matched
B-control	702	709	placebo
O	709	710	.

B-total-participants	711	715	1410
O	716	717	(
O	717	719	36
O	719	720	%
O	720	721	)
O	722	736	postmenopausal
O	737	742	women
O	743	747	were
O	748	752	then
O	753	761	enrolled
O	762	764	in
O	765	766	a
O	767	771	bone
O	772	780	substudy
O	781	784	and
O	785	795	stratified
O	796	798	at
O	799	807	baseline
O	808	817	according
O	818	820	to
O	821	826	their
O	827	833	lowest
O	834	842	baseline
O	843	844	T
O	845	850	score
O	851	853	at
O	854	859	spine
O	860	862	or
O	863	870	femoral
O	871	875	neck
O	876	877	(
O	877	884	stratum
O	885	886	I
O	886	887	:
O	888	889	T
O	890	895	score
O	896	898	at
O	899	904	least
O	905	906	-
O	906	907	1
O	907	908	·
O	908	909	0
O	909	910	;
O	911	918	stratum
O	919	921	II
O	921	922	:
O	923	924	T
O	925	930	score
O	931	933	at
O	934	939	least
O	940	941	-
O	941	942	2
O	942	943	·
O	943	944	5
O	945	948	but
O	949	953	less
O	954	958	than
O	959	960	-
O	960	961	1
O	961	962	·
O	962	963	0
O	963	964	;
O	965	972	stratum
O	973	976	III
O	976	977	:
O	978	979	T
O	980	985	score
O	986	990	less
O	991	995	than
O	996	997	-
O	997	998	2
O	998	999	·
O	999	1000	5
O	1001	1004	but
O	1005	1012	greater
O	1013	1017	than
O	1018	1019	-
O	1019	1020	4
O	1020	1021	·
O	1021	1022	0
O	1022	1023	)
O	1023	1024	.

O	1025	1030	Women
O	1031	1033	in
O	1034	1041	stratum
O	1042	1043	I
O	1044	1048	were
O	1049	1058	monitored
O	1059	1063	only
O	1063	1064	;
O	1065	1070	women
O	1071	1073	in
O	1074	1081	stratum
O	1082	1085	III
O	1086	1090	were
O	1091	1094	all
O	1095	1100	given
O	1101	1112	risedronate
O	1113	1114	(
O	1114	1116	35
O	1117	1119	mg
O	1119	1120	/
O	1120	1124	week
O	1124	1125	)
O	1125	1126	.

O	1127	1132	Women
O	1133	1135	in
O	1136	1143	stratum
O	1144	1146	II
O	1147	1151	were
O	1152	1160	randomly
O	1161	1169	assigned
O	1170	1171	(
O	1171	1172	1
O	1172	1173	:
O	1173	1174	1
O	1174	1175	)
O	1176	1178	to
O	1179	1190	risedronate
O	1191	1192	(
O	1192	1194	35
O	1195	1197	mg
O	1197	1198	/
O	1198	1202	week
O	1202	1203	)
O	1204	1206	or
O	1207	1214	matched
O	1215	1222	placebo
O	1223	1225	by
O	1226	1229	use
O	1230	1232	of
O	1233	1234	a
O	1235	1240	block
O	1241	1254	randomisation
O	1255	1263	schedule
O	1264	1267	via
O	1268	1269	a
O	1270	1273	web
O	1273	1274	-
O	1274	1279	based
O	1280	1289	programme
O	1289	1290	.

O	1291	1294	The
O	1295	1302	primary
O	1303	1310	outcome
O	1311	1313	of
O	1314	1318	this
O	1319	1322	per
O	1322	1323	-
O	1323	1331	protocol
O	1332	1340	analysis
O	1341	1342	(
O	1342	1346	done
O	1347	1351	with
O	1352	1355	all
O	1356	1361	women
O	1362	1366	with
O	1367	1368	a
O	1369	1377	baseline
O	1378	1381	and
O	1382	1383	3
O	1384	1388	year
O	1389	1392	DXA
O	1393	1403	assessment
O	1403	1404	)
O	1405	1408	was
O	1409	1412	the
B-outcome-Measure	1413	1419	effect
I-outcome-Measure	1420	1422	of
I-outcome-Measure	1423	1434	risedronate
I-outcome-Measure	1435	1441	versus
I-outcome-Measure	1442	1449	placebo
I-outcome-Measure	1450	1453	for
I-outcome-Measure	1454	1464	osteopenic
I-outcome-Measure	1465	1470	women
I-outcome-Measure	1471	1473	in
I-outcome-Measure	1474	1481	stratum
I-outcome-Measure	1482	1484	II
I-outcome-Measure	1485	1493	randomly
I-outcome-Measure	1494	1503	allocated
I-outcome-Measure	1504	1506	to
I-outcome-Measure	1507	1518	anastrozole
O	1519	1520	(
O	1520	1521	1
O	1522	1524	mg
O	1524	1525	/
O	1525	1528	day
O	1528	1529	)
O	1529	1530	.

O	1531	1540	Secondary
O	1541	1549	outcomes
O	1550	1558	included
B-outcome-Measure	1559	1565	effect
I-outcome-Measure	1566	1568	of
I-outcome-Measure	1569	1580	anastrozole
I-outcome-Measure	1581	1582	(
I-outcome-Measure	1582	1583	1
I-outcome-Measure	1584	1586	mg
I-outcome-Measure	1586	1587	/
I-outcome-Measure	1587	1590	day
I-outcome-Measure	1590	1591	)
I-outcome-Measure	1592	1594	on
I-outcome-Measure	1595	1598	BMD
O	1599	1601	in
O	1602	1607	women
O	1608	1611	not
O	1612	1621	receiving
O	1622	1633	risedronate
O	1634	1635	(
O	1635	1641	strata
O	1642	1643	I
O	1644	1647	and
O	1648	1650	II
O	1650	1651	)
O	1652	1655	and
O	1656	1658	in
O	1659	1671	osteoporotic
O	1672	1677	women
O	1678	1681	who
O	1682	1686	were
O	1687	1690	all
O	1691	1698	treated
O	1699	1703	with
O	1704	1715	risedronate
O	1716	1717	(
O	1717	1724	stratum
O	1725	1728	III
O	1728	1729	)
O	1729	1730	.

O	1731	1734	The
O	1735	1740	trial
O	1741	1743	is
O	1744	1751	ongoing
O	1751	1752	,
O	1753	1756	but
O	1757	1759	no
O	1760	1766	longer
O	1767	1777	recruiting
O	1777	1778	.

O	1779	1783	This
O	1784	1789	trial
O	1790	1792	is
O	1793	1803	registered
O	1803	1804	,
O	1805	1811	number
O	1812	1826	ISRCTN31488319
O	1826	1827	.

O	1828	1835	Between
O	1836	1839	Feb
O	1840	1841	2
O	1841	1842	,
O	1843	1847	2003
O	1847	1848	,
O	1849	1852	and
O	1853	1857	Sept
O	1858	1860	30
O	1860	1861	,
O	1862	1866	2010
O	1866	1867	,
B-total-participants	1868	1871	150
O	1872	1873	(
O	1873	1875	58
O	1875	1876	%
O	1876	1877	)
O	1878	1880	of
O	1881	1884	260
O	1885	1890	women
O	1891	1893	in
O	1894	1901	stratum
O	1902	1904	II
O	1905	1908	who
O	1909	1912	had
O	1913	1917	been
O	1918	1926	randomly
O	1927	1936	allocated
O	1937	1939	to
O	1940	1951	anastrozole
O	1952	1955	and
O	1956	1962	either
O	1963	1974	risedronate
O	1975	1977	or
O	1978	1985	placebo
O	1986	1989	had
O	1990	1998	baseline
O	1999	2002	and
O	2003	2004	3
O	2005	2009	year
O	2010	2021	assessments
O	2021	2022	.

O	2023	2025	At
O	2026	2029	the
O	2030	2036	lumbar
O	2037	2042	spine
O	2042	2043	,
B-outcome	2044	2045	3
I-outcome	2046	2050	year
I-outcome	2051	2055	mean
I-outcome	2056	2059	BMD
I-outcome	2060	2066	change
O	2067	2070	for
O	2071	2074	the
B-intervention-participants	2075	2077	77
O	2078	2083	women
O	2084	2093	receiving
O	2094	2105	anastrozole
O	2105	2106	/
O	2106	2117	risedronate
O	2118	2121	was
B-iv-cont-mean	2122	2123	1
I-iv-cont-mean	2123	2124	·
I-iv-cont-mean	2124	2125	1
I-iv-cont-mean	2125	2126	%
O	2127	2128	(
O	2128	2130	95
O	2130	2131	%
O	2132	2134	CI
O	2135	2136	0
O	2136	2137	·
O	2137	2138	2
O	2139	2141	to
O	2142	2143	2
O	2143	2144	·
O	2144	2145	1
O	2145	2146	)
O	2147	2153	versus
B-cv-cont-mean	2154	2155	-
I-cv-cont-mean	2155	2156	2
I-cv-cont-mean	2156	2157	·
I-cv-cont-mean	2157	2158	6
I-cv-cont-mean	2158	2159	%
O	2160	2161	(
O	2161	2162	-
O	2162	2163	4
O	2163	2164	·
O	2164	2165	0
O	2166	2168	to
O	2169	2170	-
O	2170	2171	1
O	2171	2172	·
O	2172	2173	3
O	2173	2174	)
O	2175	2178	for
O	2179	2182	the
B-control-participants	2183	2185	73
O	2186	2191	women
O	2192	2201	receiving
O	2202	2213	anastrozole
O	2213	2214	/
O	2214	2221	placebo
O	2222	2223	(
O	2223	2224	p
O	2224	2225	<
O	2225	2226	0
O	2226	2227	·
O	2227	2231	0001
O	2231	2232	)
O	2232	2233	.

O	2234	2237	For
O	2238	2241	the
O	2242	2247	total
O	2248	2251	hip
O	2251	2252	,
B-outcome	2253	2254	3
I-outcome	2255	2259	year
I-outcome	2260	2264	mean
I-outcome	2265	2268	BMD
I-outcome	2269	2275	change
O	2276	2279	for
O	2280	2285	women
O	2286	2295	receiving
O	2296	2307	anastrozole
O	2307	2308	/
O	2308	2319	risedronate
O	2320	2323	was
B-iv-cont-mean	2324	2325	-
I-iv-cont-mean	2325	2326	0
I-iv-cont-mean	2326	2327	·
I-iv-cont-mean	2327	2328	7
I-iv-cont-mean	2328	2329	%
O	2330	2331	(
O	2331	2332	-
O	2332	2333	1
O	2333	2334	·
O	2334	2335	6
O	2336	2338	to
O	2339	2340	0
O	2340	2341	·
O	2341	2342	2
O	2342	2343	)
O	2344	2350	versus
B-cv-cont-mean	2351	2352	-
I-cv-cont-mean	2352	2353	3
I-cv-cont-mean	2353	2354	·
I-cv-cont-mean	2354	2355	5
I-cv-cont-mean	2355	2356	%
O	2357	2358	(
O	2358	2359	-
O	2359	2360	4
O	2360	2361	·
O	2361	2362	6
O	2363	2365	to
O	2366	2367	-
O	2367	2368	2
O	2368	2369	·
O	2369	2370	3
O	2370	2371	)
O	2372	2375	for
O	2376	2381	women
O	2382	2391	receiving
O	2392	2403	anastrozole
O	2403	2404	/
O	2404	2411	placebo
O	2412	2413	(
O	2413	2414	p
O	2414	2415	=
O	2415	2416	0
O	2416	2417	·
O	2417	2421	0001
O	2421	2422	)
O	2422	2423	.

O	2424	2427	652
O	2428	2429	(
O	2429	2431	65
O	2431	2432	%
O	2432	2433	)
O	2434	2436	of
O	2437	2441	1008
O	2442	2447	women
O	2448	2450	in
O	2451	2457	strata
O	2458	2459	I
O	2460	2463	and
O	2464	2466	II
O	2467	2470	who
O	2471	2475	were
O	2476	2479	not
O	2480	2488	randomly
O	2489	2498	allocated
O	2499	2501	to
O	2502	2513	risedronate
O	2514	2517	had
O	2518	2522	both
O	2523	2531	baseline
O	2532	2535	and
O	2536	2537	3
O	2538	2542	year
O	2543	2554	assessments
O	2554	2555	.

O	2556	2561	Women
O	2562	2565	not
O	2566	2575	receiving
O	2576	2587	risedronate
O	2588	2590	in
O	2591	2598	stratum
O	2599	2600	I
O	2601	2604	and
O	2605	2607	II
O	2608	2611	who
O	2612	2620	received
O	2621	2632	anastrozole
O	2633	2634	(
O	2634	2637	310
O	2638	2643	women
O	2643	2644	)
O	2645	2648	had
O	2649	2650	a
O	2651	2662	significant
O	2663	2666	BMD
O	2667	2675	decrease
O	2676	2681	after
O	2682	2683	3
O	2684	2689	years
O	2690	2692	of
O	2693	2699	follow
O	2699	2700	-
O	2700	2702	up
O	2703	2711	compared
O	2712	2716	with
O	2717	2722	women
O	2723	2726	who
O	2727	2735	received
O	2736	2743	placebo
O	2744	2745	(
O	2745	2748	342
O	2749	2754	women
O	2754	2755	)
B-outcome	2756	2758	at
I-outcome	2759	2762	the
I-outcome	2763	2769	lumbar
I-outcome	2770	2775	spine
O	2776	2777	(
B-iv-cont-mean	2777	2778	-
I-iv-cont-mean	2778	2779	4
I-iv-cont-mean	2779	2780	·
I-iv-cont-mean	2780	2781	0
I-iv-cont-mean	2781	2782	%
O	2783	2784	[
O	2784	2785	-
O	2785	2786	4
O	2786	2787	·
O	2787	2788	5
O	2789	2791	to
O	2792	2793	-
O	2793	2794	3
O	2794	2795	·
O	2795	2796	4
O	2796	2797	]
O	2798	2800	vs
B-cv-cont-mean	2801	2802	-
I-cv-cont-mean	2802	2803	1
I-cv-cont-mean	2803	2804	·
I-cv-cont-mean	2804	2805	2
I-cv-cont-mean	2805	2806	%
O	2807	2808	[
O	2808	2809	-
O	2809	2810	1
O	2810	2811	·
O	2811	2812	7
O	2813	2815	to
O	2816	2817	-
O	2817	2818	0
O	2818	2819	·
O	2819	2820	7
O	2820	2821	]
O	2821	2822	,
O	2823	2824	p
O	2824	2825	<
O	2825	2826	0
O	2826	2827	·
O	2827	2831	0001
O	2831	2832	)
O	2833	2836	and
B-outcome	2837	2842	total
I-outcome	2843	2846	hip
O	2847	2848	(
B-iv-cont-mean	2848	2849	-
I-iv-cont-mean	2849	2850	4
I-iv-cont-mean	2850	2851	·
I-iv-cont-mean	2851	2852	0
I-iv-cont-mean	2852	2853	%
O	2854	2855	[
O	2855	2856	-
O	2856	2857	4
O	2857	2858	·
O	2858	2859	4
O	2860	2862	to
O	2863	2864	-
O	2864	2865	3
O	2865	2866	·
O	2866	2867	6
O	2867	2868	]
O	2869	2871	vs
B-cv-cont-mean	2872	2873	-
I-cv-cont-mean	2873	2874	1
I-cv-cont-mean	2874	2875	·
I-cv-cont-mean	2875	2876	8
I-cv-cont-mean	2876	2877	%
O	2878	2879	[
O	2879	2880	-
O	2880	2881	2
O	2881	2882	·
O	2882	2883	1
O	2884	2886	to
O	2887	2888	-
O	2888	2889	1
O	2889	2890	·
O	2890	2891	4
O	2891	2892	]
O	2892	2893	,
O	2894	2895	p
O	2895	2896	<
O	2896	2897	0
O	2897	2898	·
O	2898	2902	0001
O	2902	2903	)
O	2903	2904	.

O	2905	2908	106
O	2909	2910	(
O	2910	2912	79
O	2912	2913	%
O	2913	2914	)
O	2915	2917	of
O	2918	2921	149
O	2922	2927	women
O	2928	2930	in
O	2931	2938	stratum
O	2939	2942	III
O	2943	2946	had
O	2947	2948	a
O	2949	2957	baseline
O	2958	2961	and
O	2962	2963	a
O	2964	2965	3
O	2966	2970	year
O	2971	2981	assessment
O	2981	2982	.

O	2983	2986	The
B-intervention-participants	2987	2989	46
O	2990	2995	women
O	2996	3005	allocated
O	3006	3008	to
O	3009	3020	anastrozole
O	3021	3024	had
O	3025	3026	a
O	3027	3033	modest
B-outcome	3034	3037	BMD
I-outcome	3038	3046	increase
O	3047	3049	of
B-iv-cont-mean	3050	3051	1
I-iv-cont-mean	3051	3052	·
I-iv-cont-mean	3052	3053	2
I-iv-cont-mean	3053	3054	%
O	3055	3056	(
O	3056	3057	-
O	3057	3058	0
O	3058	3059	·
O	3059	3060	1
O	3061	3063	to
O	3064	3065	2
O	3065	3066	·
O	3066	3067	6
O	3067	3068	)
B-outcome	3069	3071	at
I-outcome	3072	3075	the
I-outcome	3076	3081	spine
O	3082	3090	compared
O	3091	3095	with
O	3096	3097	a
B-cv-cont-mean	3098	3099	3
I-cv-cont-mean	3099	3100	·
I-cv-cont-mean	3100	3101	9
I-cv-cont-mean	3101	3102	%
O	3103	3104	(
O	3104	3105	2
O	3105	3106	·
O	3106	3107	6
O	3108	3110	to
O	3111	3112	5
O	3112	3113	·
O	3113	3114	2
O	3114	3115	)
O	3116	3124	increase
O	3125	3128	for
O	3129	3132	the
O	3133	3135	60
O	3136	3141	women
O	3142	3151	allocated
O	3152	3154	to
O	3155	3162	placebo
O	3163	3164	(
O	3164	3165	p
O	3165	3166	=
O	3166	3167	0
O	3167	3168	·
O	3168	3171	006
O	3171	3172	)
O	3172	3173	.

O	3174	3177	For
O	3178	3181	the
B-outcome	3182	3187	total
I-outcome	3188	3191	hip
O	3191	3192	,
O	3193	3194	a
O	3195	3200	small
B-iv-cont-mean	3201	3202	0
I-iv-cont-mean	3202	3203	·
I-iv-cont-mean	3203	3204	3
I-iv-cont-mean	3204	3205	%
O	3206	3207	(
O	3207	3208	-
O	3208	3209	0
O	3209	3210	·
O	3210	3211	9
O	3212	3214	to
O	3215	3216	1
O	3216	3217	·
O	3217	3218	5
O	3218	3219	)
O	3220	3228	increase
O	3229	3232	was
O	3233	3238	noted
O	3239	3242	for
O	3243	3248	women
O	3249	3258	allocated
O	3259	3270	anastrozole
O	3271	3279	compared
O	3280	3284	with
O	3285	3286	a
B-cv-cont-mean	3287	3288	1
I-cv-cont-mean	3288	3289	·
I-cv-cont-mean	3289	3290	5
I-cv-cont-mean	3290	3291	%
O	3292	3293	(
O	3293	3294	0
O	3294	3295	·
O	3295	3296	5
O	3297	3299	to
O	3300	3301	2
O	3301	3302	·
O	3302	3303	5
O	3303	3304	)
O	3305	3313	increase
O	3314	3317	for
O	3318	3323	women
O	3324	3333	allocated
O	3334	3341	placebo
O	3341	3342	,
O	3343	3346	but
O	3347	3350	the
O	3351	3361	difference
O	3362	3365	was
O	3366	3369	not
O	3370	3381	significant
O	3382	3383	(
O	3383	3384	p
O	3384	3385	=
O	3385	3386	0
O	3386	3387	·
O	3387	3389	12
O	3389	3390	)
O	3390	3391	.

O	3392	3395	The
O	3396	3400	most
O	3401	3407	common
O	3408	3415	adverse
O	3416	3421	event
O	3422	3430	reported
O	3431	3434	was
O	3435	3445	arthralgia
O	3446	3447	(
B-outcome	3447	3454	stratum
I-outcome	3455	3456	I
O	3456	3457	:
B-cv-bin-abs	3458	3460	94
O	3461	3468	placebo
O	3469	3472	and
B-iv-bin-abs	3473	3476	114
O	3477	3488	anastrozole
O	3488	3489	;
B-outcome	3490	3497	stratum
I-outcome	3498	3500	II
O	3500	3501	:
B-cv-bin-abs	3502	3504	39
O	3505	3512	placebo
O	3512	3513	/
O	3513	3520	placebo
O	3520	3521	,
B-iv-bin-abs	3522	3524	25
O	3525	3532	placebo
O	3532	3533	/
O	3533	3544	risedronate
O	3544	3545	,
B-iv-bin-abs	3546	3548	34
O	3549	3560	anastrozole
O	3560	3561	/
O	3561	3568	placebo
O	3568	3569	,
O	3570	3573	and
B-iv-bin-abs	3574	3576	34
O	3577	3588	anastrozole
O	3588	3589	/
O	3589	3600	risedronate
O	3600	3601	;
B-outcome	3602	3609	stratum
I-outcome	3610	3613	III
O	3613	3614	:
B-iv-bin-abs	3615	3617	21
O	3618	3625	placebo
O	3625	3626	/
O	3626	3637	risedronate
O	3637	3638	,
B-iv-bin-abs	3639	3641	17
O	3642	3653	anastrozole
O	3653	3654	/
O	3654	3665	risedronate
O	3665	3666	)
O	3666	3667	.

O	3668	3673	Other
O	3674	3681	adverse
O	3682	3688	events
O	3689	3697	included
B-outcome	3698	3701	hot
I-outcome	3702	3709	flushes
O	3709	3710	,
B-outcome	3711	3719	alopecia
O	3719	3720	,
B-outcome	3721	3730	abdominal
I-outcome	3731	3735	pain
O	3735	3736	,
O	3737	3740	and
B-outcome	3741	3745	back
I-outcome	3746	3750	pain
O	3750	3751	.

O	3752	3763	Risedronate
O	3764	3779	counterbalances
O	3780	3783	the
O	3784	3790	effect
O	3791	3793	of
O	3794	3805	anastrozole
O	3805	3806	-
O	3806	3813	induced
O	3814	3818	bone
O	3819	3823	loss
O	3824	3826	in
O	3827	3837	osteopenic
O	3838	3841	and
O	3842	3854	osteoporotic
O	3855	3860	women
O	3861	3864	and
O	3865	3870	might
O	3871	3873	be
O	3874	3881	offered
O	3882	3884	in
O	3885	3896	combination
O	3897	3901	with
O	3902	3913	anastrozole
O	3914	3923	treatment
O	3924	3926	to
O	3927	3934	provide
O	3935	3937	an
O	3938	3946	improved
O	3947	3951	risk
O	3951	3952	-
O	3952	3959	benefit
O	3960	3967	profile
O	3967	3968	.

O	3969	3975	Cancer
O	3976	3984	Research
O	3985	3987	UK
O	3988	3989	(
O	3989	3993	C569
O	3993	3994	/
O	3994	3999	A5032
O	3999	4000	)
O	4000	4001	,
O	4002	4010	National
O	4011	4017	Health
O	4018	4021	and
O	4022	4029	Medical
O	4030	4038	Research
O	4039	4046	Council
O	4047	4056	Australia
O	4057	4058	(
O	4058	4067	GNT300755
O	4067	4068	,
O	4069	4078	GNT569213
O	4078	4079	)
O	4079	4080	,
O	4081	4087	Sanofi
O	4087	4088	-
O	4088	4095	Aventis
O	4095	4096	,
O	4097	4100	and
O	4101	4112	AstraZeneca
O	4112	4113	.
